
Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Charlotte faith leaders hold interfaith forum on Black and Palestinian solidarity - 2
6 Top of the line Lodgings All over The Planet, Which One Do You Concur With - 3
Fundamental Venture The board Apparatuses for Remote Groups - 4
Rescuers attempt to dig free whale stranded on Germany's Baltic coast - 5
Transform the daily grind to make life more interesting – a philosopher shares 3 strategies to help you attain the good life
Most loved Amusement Park for Small children: Which One Do You Suggest?
Eurasian cargo hub expands to capture Europe-Asia freight flows
Robyn returns to music with 'Dopamine,' her 1st single in 7 years: 'Came to save music once again'
This country music star spent years hiding his sexuality. Coming out — and beating addiction — has made his soul feel '20 pounds lighter.'
A few Exemplary Chinese Dishes, Which Are Famous Around the world
Volcanic eruption led to the Black Death, new research suggests
8 key takeaways from Savannah Guthrie's 'Today' interview on the disappearance of her mother
The Most recent Microsoft Surface Genius PC: Ideal for Very good quality Planning and Gaming Needs
If everyone on Earth sat in the ocean at once, how much would sea level rise?











